Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 5, 4309

TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients With Non-Alcoholic Fatty Liver Disease

Affiliations

TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients With Non-Alcoholic Fatty Liver Disease

Yang-Lin Liu et al. Nat Commun.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN. Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.

Similar articles

See all similar articles

Cited by 108 PubMed Central articles

See all "Cited by" articles

References

    1. Anstee Q. M., Targher G. & Day C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013). - PubMed
    1. Musso G., Gambino R., Cassader M. & Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011). - PubMed
    1. Ekstedt M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006). - PubMed
    1. Loomba R. & Sanyal A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013). - PubMed
    1. Hirschhorn J. N. & Gajdos Z. K. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annu. Rev. Med. 62, 11–24 (2011). - PubMed

Publication types

MeSH terms

Feedback